Star Update Podcast - Cardiology News Summaries

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysisof randomised controlled trials Lancet-2025 Sep 13;406(10508):1128-1137. doi: 10.1016/S0140-6736(25)01592-2. Epub 2025 Aug 30. Abstract Background:   The effects of β-blocker therapy on clinical outcomes in patients with myocardial infarction and mildly reduced (40-49%) left ventri...

Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study DOI:  10.1002/ccd.70503   Abstract Background:  The safety and efficacy of aspirin combined with ticagrelor or clopidogrel remain unclear in ST-segment elevation myocardial infarction (STEMI) patients with Diabetes melli...

Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Systematic Review and Meta-Analysis DOI:  10.1177/10760296261422490 Abstract Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) remains debated. While DAPT with a...

Heart Failure Outcomes with SGLT2 Inhibitors in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis DOI: https://doi.org/10.3390/medicina62010069 Abstract Background and Objectives:  Type 2 diabetes mellitus (T2DM) substantially increases the risk of heart failure (HF) and worsens its prognosis. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for glycemic con...

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failurewith reduced ejection fraction: a nationwide cohort study Lancet Reg Health Eur . 2025 Oct 27:60:101510. doi:10.1016/j.lanepe.2025.101510. Abstract Background:  Heart failure with reduced ejection fraction (HFrEF) guidelines recommend early initiation of four foundational therapies-re...

Lower Ticagrelor Dosing in the Dual Antiplatelet Regimen for Neurointerventional Procedures https://doi.org/10.1136/jnis-2024-022536  Abstract Background  Ticagrelor, a P2Y12 inhibitor, offersa rapid onset and consistent platelet inhibition, making it a viable alternative for dual antiplatelet therapy (DAPT). The optimal ticagrelor dose for neurointerventional procedures, however, remains unclear....

Impact of Early Percutaneous Coronary Intervention on Long-Term Survival in Patients With Acute Myocardial InfarctionCureus 18(1): e101145. DOI 10.7759/cureus.101145   Abstract Background : Early percutaneous coronary intervention(PCI) is the recommended standard of care for acute myocardial infarction (AMI), but long-term outcomes in mixed real-world cohorts remain underreported. This study evalu...

Circadian variation in ST-segment elevation myocardial infarction: a nationwide analysis of onset, treatmentdelays, and culprit artery patterns Pol Arch Intern Med. 2026 Jan 7:17188. doi: 10.20452/pamw.17188 Abstract Introduction: ST-segment elevation myocardialinfarction (STEMI) onset follows a circadian rhythm, yet data from large contemporary national registries remain limited, particularly reg...

β-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis Eur J Clin Pharmacol. 2025 Dec;81(12):1807-1817. Abstract Background and objective:  While current clinicalguidelines generally advocate for beta-blocker therapy following acute myocardial infarction (AMI), conflicting findings have surfaced through large-scale observational studies and m...

Intravascular imaging-guided percutaneous coronary intervention for acute myocardial infarction according to ACC/AHA lesion classification https://doi.org/10.1016/j.rec.2025.12.001 Abstract Introduction and objectives: Despite the favorableprognosis associated with intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI) for complex coronary lesions, it is still unclear whether...

Pharmacological Evaluation of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin Pretreatment on Infarct Artery Flowin Patients with Acute STEMI   Pharmaceuticals   2025 ,  18 (12), 1856;  https://doi.org/10.3390/ph18121856 Abstract Background and Objectives : Dual antiplatelet therapy(DAPT) with aspirin and a P2Y12 inhibitor is standard in ST-segment elevation myocardial infarction (STEMI). Gu...

Incidence and In-Hospital Outcomes of Bradycardia or Atrioventricular Conduction Disorder in Patients With Type 2Myocardial Infarction: A Nationwide Inpatient Analysis https://doi.org/10.1002/joa3.70243 ABSTRACT Background Type 2 myocardial infarction (T2MI), caused by an imbalancebetween oxygen supply and demand without significant coronary obstruction, is increasingly recognized yet remains unde...

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure N Engl J Med . 2025 Nov 13;393(19):1901-1911. doi: 10.1056/NEJMoa2505985  Abstract Background:  The evidence supporting beta-blockertherapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. Methods:  In an open-label, randomized t...

Prognostic Implications of Heart Failure Rehospitalization in Adults with CHD & Clinical Benefits of Medical Therapy https://doi.org/10.1016/j.ijcchd.2025.100640  ABSTRACT Background   The risk factors for heart failure (HF) rehospitalization, and the effect of guideline directed medical therapy (GDMT)are poorly understood in adults with congenital heart disease (ACHD). We aimed to describe th...

Differential Impact of Metoprolol Formulations on Heart Failure Outcomes: A Multi-center Study https://doi.org/10.1016/j.yjcafi.2025.10.010  ABSTRACT   Background  Despite widespread use of metoprolol formulations in heart failure (HF), direct comparative evidence of theirclinical outcomes remains limited.   Methods In this retrospective cohort study using the TriNetX Research Network (2010-2024),...

Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: apropensity score-matched analysis https://doi.org/10.1093/eurheartj/ehaf784.2070   Abstract Background Cardiogenic shock secondary to acute myocardial infarction (AMICS) is a critical condition with significant hemostatic challenges. Despite the widespread use of P2Y12 inhibitors, cur...

Drug Utilization Patterns and Adherenceto Guideline-Directed Therapy in Acute Myocardial Infarction: A ProspectiveObservational Study International Journal of Life Sciences, Biotechnology andPharma Research Vol. 14, No. 10, October 2025 DOI:10.69605/ijlbpr_14.10.2025.11 ABSTRACT Background: Acute myocardial infarction (AMI) is aleading cause of morbidity and mortality worldwide. Effective pharmaco...

1-Month Versus 12-Month Dual Antiplatelet Therapy for Patients with Chronic Total Occlusion After Successful Percutaneous Coronary Intervention Drugs Aging . 2025 Oct;42(10):975-985. doi:10.1007/s40266-025-01235-z.   Abstract Purpose:  Compared with long-term dual antiplatelet therapy (DAPT, aspirin with clopidogrel or ticagrelor), short-termDAPT followed by single antiplatelet therapy (SAPT, clop...

 Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation for Bioprosthetic Valve Failure https://www.jacc.org/doi/10.1016/j.jcin.2025.09.018 ABSTRACT Background: Single antiplatelet therapy (SAPT) is the standard treatment after transcatheter aortic valve intervention (TAVI). However, valve-in-valve transcatheter aortic valve intervention to treat surgical bioprosthes...

Impact of digoxin versus beta-blocker in patients withcoexistent atrial fibrillation and heart failure: a target trial emulation BMC Med . 2025 Oct 21;23(1):575. doi: 10.1186/s12916-025-04408-0.   Abstract Background:  This study aimed to compare the impact of digoxin versus beta-blocker on adverse clinical outcomes in patients with coexisting atrial fibrillation (AF) and heart failure (HF). Metho...

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysisof randomised controlled trials Lancet. 2025 Sep 13;406(10508):1128-1137. Abstract Background: The effects of β-blocker therapy on clinicaloutcomes in patients with myocardial infarction and mildly reduced (40-49%) left ventricular ejection fraction (LVEF) are largely unknown. Four...

Comparison between clopidogrel and ticagrelor in CYP2C19 loss-of-function alleles coronary artery disease andstroke patients: a meta-analysis Eur J Clin Pharmacol. 2025 Sep;81(9):1241-1256. Abstract Background:  It is suggested that in patientswith coronary artery diseases (CAD) and stroke, the use of ticagrelor and aspirin may perform better than clopidogrel and aspirin regarding the risk of thro...

Angiotensin receptor-neprilysin inhibitors and mortality among patients with heart failure with reducedejection fraction https://doi.org/10.1016/j.amjcard.2025.08.063 Abstract Background While trial evidence supports the benefit of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in heart failurewith reduced ejection fraction (HFrEF), its effectiveness in routine clinical practice is less...

The use of beta-blockers for heart failure with reduced ejection fraction in the era of SGLT2 inhibitors - are westill afraid to up-titrate? Heart Vessels . 2025 Sep;40(9):797-804.doi: 10.1007/s00380-025-02525-7. Abstract Beta-blockers are one of the four major pillars of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). The therapy has presented t...

Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial Eur Heart J 2025 Aug 1;46(29):2894-2902. doi: 10.1093/eurheartj/ehaf170. Abstract Background and aims: This study aims to report theeffects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuati...